Final Analysis: Randomized, Blinded, Placebo-Controlled Phase Ii Trial Of Sorafenib With And Without Mapatumumab In Patients With Advanced Hepatocellular Carcinoma (Hcc).
JOURNAL OF CLINICAL ONCOLOGY（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要